Your browser doesn't support javascript.
loading
Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Brown, Jacob T; Bishop, Jeffrey R; Sangkuhl, Katrin; Nurmi, Erika L; Mueller, Daniel J; Dinh, Jean C; Gaedigk, Andrea; Klein, Teri E; Caudle, Kelly E; McCracken, James T; de Leon, Jose; Leeder, J Steven.
Afiliação
  • Brown JT; Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota College of Pharmacy, Duluth, Minnesota, USA.
  • Bishop JR; Department of Experimental and Clinical Pharmacology, College of Pharmacy, Department of Psychiatry, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
  • Sangkuhl K; Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
  • Nurmi EL; Division of Child and Adolescent Psychiatry, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California, USA.
  • Mueller DJ; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Dinh JC; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
  • Gaedigk A; Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
  • Klein TE; Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
  • Caudle KE; School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
  • McCracken JT; Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
  • de Leon J; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Leeder JS; Division of Child and Adolescent Psychiatry, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California, USA.
Clin Pharmacol Ther ; 106(1): 94-102, 2019 07.
Article em En | MEDLINE | ID: mdl-30801677
Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno do Deficit de Atenção com Hiperatividade / Inibidores da Captação Adrenérgica / Citocromo P-450 CYP2D6 / Cloridrato de Atomoxetina Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Clin Pharmacol Ther Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno do Deficit de Atenção com Hiperatividade / Inibidores da Captação Adrenérgica / Citocromo P-450 CYP2D6 / Cloridrato de Atomoxetina Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Clin Pharmacol Ther Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos